LIBRIUM
CHLORDIAZEPOXIDE HYDROCHLORIDE
Approval overview LIBRIUM is listed in Drugs@FDA under application 012249 (NDA).
Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient CHLORDIAZEPOXIDE HYDROCHLORIDE Form and strength CAPSULE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor VALEANT PHARM INTL Submission history Latest submission status date: 2016-12-16 00:00:00.
Structured Monograph
Clinical summary
Approval overview LIBRIUM is listed in Drugs@FDA under application 012249 (NDA). Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient CHLORDIAZEPOXIDE HYDROCHLORIDE Form and strength CAPSULE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor VALEANT PHARM INTL Submission history Latest submission status date: 2016-12-16 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: 901 REQUIRED
Interaction Notes
- No interaction notes stored yet.